跳至主要内容
临床试验/NCT03245970
NCT03245970
撤回
早期 1 期

Use of Impedance Cardiography to Decrease the Risk of Preeclampsia

University of Tennessee Medical Center1 个研究点 分布在 1 个国家2017年4月24日

概览

阶段
早期 1 期
干预措施
Labetalol Hydrocholoride 200 mg orally every 12 hours
疾病 / 适应症
Chronic Hypertension Complicating Pregnancy (Diagnosis)
发起方
University of Tennessee Medical Center
试验地点
1
主要终点
Rates of preeclampsia in chronically hypertensive pregnant women
状态
撤回
最后更新
5年前

概览

简要总结

To determine if the use of impedance cardiography can identify appropriate medications for use in treating chronic hypertensive patients to decrease the risk of preeclampsia.

详细描述

Impedance cardiography helps determine whether vasoconstriction or an elevated cardiac output is occurring. The test is easy to perform and non invasive. The treatment for an elevated cardiac output in pregnancy is a beta-blocker while a vasodilator is used for vasoconstriction. If a beta-blocker is given to someone that vasoconstricted, this might make the cardiovascular parameters worse, leading to no improvement in future pregnancy issues. Likewise, if a vasoconstricting drug is given to someone with an elevated cardiac output, it could potentially make the cardiovascular parameters worse. All centers in the United States that choose to prescribe an antihypertensive medication for use in pregnancy do so by trial and error, whereas impedance cardiography can help the clinician choose the best medication from the start. Many pregnant patient patients have chronic hypertension and this population is at increased risk for superimposed preeclampsia and other pregnancy complications. The current recommendation for pregnancy is to NOT treat mild hypertension because studies have not shown any benefit. These studies, have also not shown any harm. Prior studies that have shown no benefit to treatment of mild hypertension in pregnancy may be hampered by choosing the wrong antihypertensive medication, thereby not improving the rate of superimposed preeclampsia and other pregnancy related complications.

注册库
clinicaltrials.gov
开始日期
2017年4月24日
结束日期
2020年2月29日
最后更新
5年前
研究类型
Interventional
研究设计
Parallel
性别
Female

研究者

入排标准

入选标准

  • Pregnant patients 18-51 years old Less than 20 weeks gestation with mild chronic hypertension - Not on antihypertensive medications

排除标准

  • Patients with an allergy to antihypertensive medication or contraindication for their usage such as certain cardiac or neurologic disorder during pregnancy Patients who have a blood pressure 140/90 or greater -

研究组 & 干预措施

Treatment Arm

Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years. Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily

干预措施: Labetalol Hydrocholoride 200 mg orally every 12 hours

Treatment Arm

Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years. Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily

干预措施: Nifedipine 60 mg orally daily

Treatment Arm

Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years. Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily

干预措施: Atenolol 25 mg daily

结局指标

主要结局

Rates of preeclampsia in chronically hypertensive pregnant women

时间窗: 2 years

Rates of preeclampsia in chronically hypertensive pregnant women

研究点 (1)

Loading locations...

相似试验